[Is intermittent peritoneal dialysis with icodextrin a valid option in the long-term treatment of refractory congestive heart failure?]. / La dialisi peritoneale intermittente con i icodestrina e' una valida opzione nel trattamento a lungo termine dello scompenso cardiaco congestizio refrattario?

Refractory congestive heart failure (CHF) is affected by a very high morbidity and mortality. We report our experience in the long-term treatment of refractory CHF (NYHA class IV) by means of intermittent peritoneal dialysis (PD) with icodextrin (ICO) solutions in 4 male patients with a mean age of 71.5 + or - 5.6 (standard deviation) years and with a variable degree of chronic renal failure: 1 nocturnal exchange with ICO in 3 patients and 2 exchanges (ICO + isotonic dextrose solution) in 1 patient. The mean PD follow-up period was 24.3 + 15.6 months. After stabilization on PD, all patients had a statistically significant increase in daily diuresis (from 587.5 + or - 165.2 to 1700.0 + or - 141.4 mL, p < 0.003), a statistically significant decrease in body weight (11.3 + or - 3.4 kg, p < 0.007), and a statistically significant improvement in NYHA class (from 4.0 + or - 0.0 to 2.5 + or - 2.6, p < 0.01). Three patients had no hospitalizations due to cardiac illness in the PD follow-up period. No episodes of peritonitis occurred. Three patients died after 11, 13 and 43 months of PD treatment: 2 because of sudden death and 1 because of neoplastic cachexia. No death could be attributed to any complication related to PD treatment. Intermittent PD with ICO solutions can be proposed as a long-term treatment modality for refractory CHF. It allows an improvement in quality - if not quantity - of life. Randomized controlled trials are needed to confirm the evidence derived from case reports.

[A particular case of hemodialysis with a single-pass batch system]. / Un caso particolare di emodialisi con un single pass batch system.

The GENIUS 90 Therapy System (GENIUS) (Fresenius Medical Care, Bad Homburg, Germany) is a mobile dialysis machine with a 90-liter, thermally insulated glass tank. Fresh dialysis fluid is prepared by mixing sterile ingredients (electrolytes and glucose) with preheated ultrapure water. Here we report the case of a 60-year-old hemodialysis patient who was hospitalized in our unit in November 2005 because of an ischemic stroke affecting the left temporal-parietal-occipital region of the brain. The persisting clinical features included right hemiplegia, motor aphasia, epilepsy and stage I coma. The patient started thrice-weekly GENIUS hemodialysis treatment (about 270 sessions to date) in his hospital room with no continuous nursing assistance. In conclusion, GENIUS is able to offer user-friendly, high-quality and adequate dialysis treatment.